XLO
XLO
NASDAQ · Biotechnology

Xilio Therapeutics Inc

$0.54
+0.02 (+4.04%)
As of Feb 8, 2:20 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 12.59M 12.91M 9.78M
Net Income -1,338,243 -1,683,285 -1,199,258
EPS
Profit Margin -10.6% -13.0% -12.3%
Rev Growth -1.9% -7.4% -8.7%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 16.15M 16.94M 14.90M
Total Equity 15.37M 18.19M 17.29M
D/E Ratio 1.05 0.93 0.86
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -1,969,871 -1,762,148 -1,377,431
Free Cash Flow -1,414,748 -1,276,245 -1,101,740